{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:37:49Z","timestamp":1784914669271,"version":"3.55.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The treatment of multiple myeloma (MM) has significantly advanced; however, the underlying genetic mechanisms remain elusive. Clonal events and genetic alterations are recognized as pivotal in the pathogenesis of MM. It is now understood that a multitude of gene mutations, including those affecting RAS, <jats:italic>TP53<\/jats:italic>, <jats:italic>RB1<\/jats:italic>, and 1q21 amplification, are prevalent in this disease. The incorporation of several high-risk genetic factors into the Second Revision of the International Staging System (R<jats:sup>2<\/jats:sup>-ISS) underscores the prognostic significance of genetic aberrations in MM. The retinoblastoma gene (<jats:italic>RB1<\/jats:italic>), located in 13q14, encodes the retinoblastoma protein (pRB), a tumor suppressor that regulates cell cycle progression. Deletion of <jats:italic>RB1<\/jats:italic>, which is a frequent event in MM, contributes to tumorigenesis by disrupting cell cycle control. In this respect, <jats:italic>RB1<\/jats:italic> loss has been implicated in the progression of MM through its influence on interleukin-6 (IL-6) secretion and cell proliferation. This review comprehensively summarizes the role of <jats:italic>RB1<\/jats:italic> in MM and expounds on the potential of targeting <jats:italic>RB1<\/jats:italic> as a therapeutic strategy for this malignancy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1415972","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:13:45Z","timestamp":1732684425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The significance of RB1 in multiple myeloma"],"prefix":"10.3389","volume":"15","author":[{"given":"Yiwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clml.2016.12.001","article-title":"Prognostic implications of monosomies in patients with multiple myeloma","volume":"17","author":"Shin","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER(+) breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166647","article-title":"RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis","volume":"133","author":"Wang","year":"2023","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12920-023-01721-6","article-title":"RB1 screening of retinoblastoma patients in Sri Lanka using targeted next generation sequencing (NGS) and gene ratio analysis copy enumeration PCR (GRACE-PCR)","volume":"16","author":"Kugalingam","year":"2023","journal-title":"BMC Med Genomics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl9794","article-title":"RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer","volume":"8","author":"Miao","year":"2022","journal-title":"Sci Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3960\/jslrt.23047","article-title":"Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma","volume":"64","author":"Uryu","year":"2024","journal-title":"J Clin Exp Hematop"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1757330","article-title":"Cytogenetic abnormalities in\u00a0patients with newly diagnosed multiple myeloma as a secondary primary Malignancy: a retrospective study","volume":"25","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41467-024-45000-z","article-title":"Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features","volume":"15","author":"Terragna","year":"2024","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1421760","article-title":"PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise","volume":"59","author":"Ramakrishnan","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/genes10110879","article-title":"The RB1 story: characterization and cloning of the first tumor suppressor gene","volume":"10","author":"Berry","year":"2019","journal-title":"Genes (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00335-017-9689-4","article-title":"The human retinoblastoma susceptibility gene (RB1): an evolutionary story in primates","volume":"28","author":"Viana","year":"2017","journal-title":"Mamm Genome"},{"key":"B22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.stem.2014.10.019","article-title":"Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis","volume":"16","author":"Kareta","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.10.021","article-title":"An RB-EZH2 complex mediates silencing of repetitive DNA sequences","volume":"64","author":"Ishak","year":"2016","journal-title":"Mol Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00707-8","article-title":"Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers","volume":"5","author":"Salvadores","year":"2024","journal-title":"Nat Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/gad.282145.116","article-title":"RB1: a prototype tumor suppressor and an enigma","volume":"30","author":"Dyson","year":"2016","journal-title":"Genes Dev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40246-023-00529-w","article-title":"Genetics in ophthalmology: molecular blueprints of retinoblastoma","volume":"17","author":"Markovi\u0107","year":"2023","journal-title":"Hum Genomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"a008904","DOI":"10.1101\/cshperspect.a008904","article-title":"Signaling pathways that control cell proliferation","volume":"5","author":"Duronio","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.07.012","article-title":"Patterns in the tapestry of chromatin-bound RB","volume":"34","author":"Sanidas","year":"2024","journal-title":"Trends Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1565","article-title":"Relevance of pRB loss in human Malignancies","volume":"28","author":"Mandigo","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers16081558","article-title":"Therapeutic strategies for RB1-deficient cancers: intersecting gene regulation and targeted therapy","volume":"16","author":"Huang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"17588359231220511","DOI":"10.1177\/17588359231220511","article-title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts","volume":"16","author":"Geissler","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061196","article-title":"p15(PAF) is an Rb\/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression","volume":"8","author":"Chang","year":"2013","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.02.059","article-title":"Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining","volume":"10","author":"Cook","year":"2015","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1101\/gad.288282.116","article-title":"RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1","volume":"30","author":"V\u00e9lez-Cruz","year":"2016","journal-title":"Genes Dev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/gad.211326.112","article-title":"The retinoblastoma protein induces apoptosis directly at the mitochondria","volume":"27","author":"Hilgendorf","year":"2013","journal-title":"Genes Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.3889","article-title":"Rb deficiency accelerates progression of carcinoma of the urinary bladder in vivo and in vitro through inhibiting autophagy and apoptosis","volume":"50","author":"Wang","year":"2017","journal-title":"Int J Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/gad.206227.112","article-title":"Loss of RBF1 changes glutamine catabolism","volume":"27","author":"Nicolay","year":"2013","journal-title":"Genes Dev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.635","article-title":"Control of glutamine metabolism by the tumor suppressor Rb","volume":"33","author":"Reynolds","year":"2014","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","first-page":"113198","DOI":"10.1016\/j.celrep.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02688-5","article-title":"Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials","volume":"24","author":"Panagiotou","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.20123344","article-title":"Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore","volume":"126","author":"Lim","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246322","article-title":"Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma","volume":"16","author":"Lee","year":"2021","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.exphem.2015.11.006","article-title":"Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells","volume":"44","author":"He","year":"2016","journal-title":"Exp Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.5.1198.1198","article-title":"Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia","volume":"78","author":"Klein","year":"1991","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03798-7","article-title":"Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis","volume":"78","author":"Gonzalez-Meljem","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14258","article-title":"The SASP factor IL-6 sustains cell-autonomous senescent cells via a cGAS-STING-NF\u03baB intracrine senescent noncanonical pathway","volume":"23","author":"Herbstein","year":"2024","journal-title":"Aging Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2013.130743","article-title":"Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true","volume":"60","author":"Neemat","year":"2014","journal-title":"Clin Lab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.12.3654.3654","article-title":"Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma","volume":"83","author":"Zhang","year":"1994","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1359041","article-title":"The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.blre.2023.101161","article-title":"Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances","volume":"64","author":"Lang","year":"2024","journal-title":"Blood Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221140320","article-title":"Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting","volume":"29","author":"Lipe","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B56","article-title":"Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias","volume":"8","author":"Corradini","year":"1994","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402609","article-title":"Alterations of the cyclin D1\/pRb\/p16(INK4A) pathway in multiple myeloma","volume":"16","author":"Kr\u00e4mer","year":"2002","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G(1) arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.apsb.2020.05.001","article-title":"Selective inhibition of CDK4\/6: A safe and effective strategy for developing anticancer drugs","volume":"11","author":"Yuan","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B64","doi-asserted-by":"publisher","first-page":"114024","DOI":"10.1016\/j.ejmech.2021.114024","article-title":"Discovery of novel and orally bioavailable CDK 4\/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma","volume":"228","author":"Yuan","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0264","article-title":"SETDB1 modulates degradation of phosphorylated RB and anticancer efficacy of CDK4\/6 inhibitors","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1415972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:13:50Z","timestamp":1732684430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1415972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2024.1415972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1415972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"article-number":"1415972"}}